Could a cancer drug ease heart strain in rare genetic disease?
NCT ID NCT07445347
First seen Mar 17, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This study looks at whether the drug bevacizumab can help people with hereditary hemorrhagic telangiectasia (HHT) who have severe liver issues causing high heart output and possible heart failure. Researchers will track heart function before and after treatment in about 111 participants from French hospitals. The goal is to measure if the drug improves heart strain and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre hospitalier universitaire de Poitiers
Poitiers, 86000, France
Conditions
Explore the condition pages connected to this study.